ABCG2 and neoplasm: While much has been accomplished in the development of specific and potent inhibitors of ABC transporters, few of these compounds have been applied to clinical trials, and those that have often result in off target toxicities, likely due to inhibition of ABC transporters not associated with the patients’ tumour.